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Correlates of protection (CoPs) against infection by primate lentiviruses remain undefined. Modest protection
against HIV-1 was observed in one human vaccine trial, whereas previous trials and vaccine-challenge experiments
in non-human primates have yielded inconsistent but intriguing results. Although high levels of neutralizing
antibodies are known to protect macaques from mucosal and intravenous viral challenges, antibody or other
adaptive immune responses associated with protection might also be mere markers of innate immunity or
susceptibility. Specific strategies for augmenting the design of both human trials and animal experiments could
help to identify mechanistic correlates of protection and clarify the influences of confounding factors. Robust
protection may, however, require the combined actions of immune responses and other host factors, thereby
limiting what inferences can be drawn from statistical associations. Here, we discuss how to analyze immune
protection against primate lentiviruses, and how host factors could influence both the elicitation and effectiveness
of vaccine-induced responses.
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Contradictory trends in pre-clinical and clinical research
on HIV-1 prevention
A goal of medical research is to find causes: as noted
already by Claude Bernard, statistical patterns are an in-
sufficient basis for saving lives [1]. This insight should
guide research on prevention of HIV-1 transmission,
which remains urgent because every year 2–3 million
more people become infected. Of four large-scale human
vaccine efficacy trials, only the fourth showed some sta-
tistically subtle protection, although each of them has
yielded intriguing statistical associations. None has
shown dampening of viral replication in cases of infec-
tion [2-5]. In contrast, control of viremia is regularly
achieved by different vaccine approaches in the simian
experimental models of HIV-1 infection [6-10]. There,
cytotoxic T-lymphocyte (CTL) responses generally cor-
relate with viremic control, whereas protection from in-
fection is linked to neutralizing antibodies (NAbs)
[6,9,11]. Protection by NAbs has also been directly* Correspondence: pek2003@med.cornell.edu
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distribution, and reproduction in any mediumdemonstrated through passive immunization of maca-
ques [12-14], but vaccination of humans or animals has
not yet elicited broadly active potent neutralization
responses [15].
An overview therefore yields a paradoxical picture:
the CTL responses that are readily induced in humans
have not dampened viral loads while the, at most, mod-
est protection afforded by one vaccine occurred in the
absence of strong and broad neutralizing responses.
Furthermore, NAb responses, although active against
only a subset of sensitive HIV-1 strains (tier 1), were
induced more strongly in an earlier human trial in
which there was no protection from infection [16]. The
outcomes of human trials have sometimes been
explored through new studies in non-human primates.
Vaccine experiments have also been interpreted in the
light of post-trial analyses that have identified immune
variables associated with distinct risks [3,4,6,9,16-18].
Here we compare the outcomes of human trials and
animal experiments, and we discuss how the design and
analysis of both types of vaccine research could be
improved.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Statisticians and vaccinologists have used the terms
surrogate and correlate of protection in contradictory
ways. The terminology was recently unified, although
omitting the term surrogate [19]. In a vaccine trial or
experiment, a correlate of risk (CoR) is the broadest
term, covering both reduced and increased risk. It
includes immune responses to the vaccine that correl-
ate with a low risk of the endpoint, be that acquisition
of infection or an elevated viral load. A correlate of
protection (CoP) is a special case of an inverse CoR: a
CoP must be responsive to alteration through vaccin-
ation, and it must predict the vaccine efficacy based on
comparisons of vaccinees and controls. A CoR in the
vaccine group can be hypothesized to be a CoP, but a
CoR is not a CoP if it merely tracks pathogen exposure
or intrinsic susceptibility to infection or disease. Hence
a genetic CoR (in the case of HIV-1 infection, for ex-
ample, homozygozity for the CCR5Δ32 allele) cannot
be a CoP, although it may confer better protection than
any vaccine.
There are two kinds of CoPs: mCoPs (mechanistic)
constitute the protective immune variable itself, while
nCoPs (non-mechanistic) are statistically associated with
the mechanistic factor without directly conferring pro-
tection. Thus an nCoP can, for example, share a cause
with the mCoP, be caused by the mCoP, or contribute as
a partial, possibly necessary but not sufficient, cause of
the mCoP.
The two kinds of CoP are suggested to be mutually ex-
clusive [19]. This distinction can, however, become intri-
cate. For example, if mucosal IgG NAbs protect against
vaginal transmission, and IgG in the vaginal mucosa is
largely transudated from plasma, would plasma IgG
NAbs then be merely an nCoP? The answer depends on
how many links in the causal chain one elects to include
in the mechanism of protection. In practice, because
plasma and vaginal IgG titers are imperfectly correlated,
plasma NAbs might be a poor predictor of protection
against vaginal challenge, i.e. not even an nCoP [20].
Furthermore, NAbs are a subset of total Env-reactive
Abs. If NAbs constitute the mCoP, and there is a correl-
ation between neutralizing and total Env-specific Abs,
then the nCoP would be what remains of the total Env
Abs after subtraction of the NAb component. In that
example, the inclusive CoP and the mCoP would be
more easily determined than the nCoP. In other cases,
an nCoP might be more readily detected. For example,
CD8+ effector memory T-cells (TEM) could be analyzed
in bronchoalveolar lavage and used to track the mCoP, i.
e., the corresponding prevalence of such cells at the less
readily accessible rectal site of virus deposition [8].
When the mCoP involves multiple factors, however,
each by itself unable to tip the balance against infection,the mutual exclusivity criterion again becomes problem-
atic. Thus, although each factor individually might be a
good marker without being mechanistically sufficient,
and hence would qualify as an nCoP, it would still be a
component of, and therefore overlap with, the mCoP.
Divergent outcomes of human trials
In the clinical trials Vax003 (a cohort of intravenous-
drug abusers) and Vax004 (sexually exposed subjects),
volunteers were immunized with recombinant outer en-
velope glycoprotein, gp120, from two HIV-1 strains. Al-
though the vaccine did not protect in either trial (0-6%
vaccine efficacy), post-trial analyses of serum samples
from the Vax004 cohort showed that Ab reactivity with
the CD4-binding site (CD4bs) on gp120, as well as
antibody-dependent cell-mediated viral inhibition
(ADCVI), correlated inversely with the risk of infection
[3,21]. One explanation would be that weak anti-gp120
antibody (Ab) responses increased the rate of infection,
while strong responses reduced it, the net infection rate
approximating that for controls. Another explanation
would be that Ab responses to gp120 were associated
with an innate immune or other resistance variable that
is not affected by the vaccine and that protects at high
but not at low levels. Had this variable been known, it
should have correlated with infection rates similarly in
the vaccinee and placebo groups. Yet another possibility
is that the vaccine, through a mechanism distributed
over the entire group of vaccinees, increased susceptibil-
ity to infection (cf. [22]), but that such an effect was
counteracted by the stronger anti-gp120 responses. Fi-
nally, the high or low reactivities with gp120, or both,
could be mere markers of other vaccine-induced
responses that directly reduced or increased the infec-
tion rate, respectively (Figure 1).
The vaccine in the STEP trial consisted of an adeno-
virus vector, carrying the HIV-1 genes gag, pol, and nef,
and was intended to induce cellular immunity. Vacci-
nees and controls who became infected got similar viral
loads, but vaccination was associated with a modestly
increased risk of infection [2,23]. Intriguingly, the
increased infection risk correlated weakly with pre-
existing Ab titers to the adenovirus vector among uncir-
cumcised male vaccinees, while such titers inversely
correlated with the risk of infection in the control
group [24]. A partly analogous effect was later observed
in a macaque experiment: monkeys that were chronic-
ally infected with a host-range mutant of adenovirus
type 5 (Ad5) and then immunized with a replication-
defective Ad5 SIVmac239 Gag-Pol-Nef vaccine showed
increased susceptibility to a sub-preputial penile inocu-
lation with low-dose SIVmac251. Unlike in the STEP
trial, however, the acute-phase viral loads were reduced
in the vaccinated macaques [18]. In another simian
Figure 1 Dissecting direct from indirect effects of vaccination by comparing with irrelevant immunization. Each square or trapezoid
(placebo controls in red, vaccinees in blue) represents the risk of infection on the y-axis. Ab response to the HIV-1 (vaccinees) or irrelevant
immunogen (both groups) is represented on the x-axis. The vaccine gives zero net protection: the areas of the squares and trapezoids are
identical. A. Strong Ab responses to HIV-1 immunogens reduce and weak ones increase risk. The risk of infection does not vary with the response
to an irrelevant immunogen for the placebo cases. B. The risk varies similarly with Ab responses to the irrelevant immunogen in placebo and
vaccine groups. The associated causal factor could be an aspect of innate immunity or a genetically determined influence on the susceptibility to
infection. C. The stronger the antibody response to the vaccine, the lower the infection risk (light blue trapezoid). This protective effect is
counteracted by an infection-enhancing effect (dark blue), e.g. inflammation or greater proliferation of target cells upon viral exposure (cf. [22]).
Since both effects are caused by the HIV-1 immunogens, the infection risk does not vary with the irrelevant Ab response in the placebo group.
D. The Ab responses are indirect markers of a vaccine-induced protective effect that is not mediated by antibodies. As in A, a high HIV-1-specific
Ab response is associated with a reduced risk of infection, a low response with an increased risk. As in B these Abs are not causally responsible.
Unlike in B, however, they are markers of an immune factor that is induced by the vaccine. The infection risk, therefore, does not vary with the
irrelevant Ab response among the placebo controls, but it does vary with both the irrelevant and the HIV-1-specific Ab responses among the
vaccinees.
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tected against rectal challenge with repeated low-dose
SIVsmE660 nor dampened viral loads, thereby also
partly reproducing the STEP trial results [25]. The early
post-vaccination CD8+ and CD4+ T-cell responses were
broad but the anamnestic post-infection responses were
narrow, perhaps an indicator of why there was no con-
trol of virus replication [25].
The vaccine regimen in the RV144 trial involved prim-
ing with a canarypox vector expressing the HIV-1 Gag,
Pol and partial Env proteins (gp120 was directly fused to
the transmembrane domain of gp41), and then boosting
with gp120 derived from viruses of Clades B and E [5].
In contrast to its Vax and STEP predecessors, the RV144
trial did show some protection from infection (31%), but
this was significant (p = 0.04) only when subjects who
had become infected between enrollment and the first
immunization were excluded from the vaccinee and pla-
cebo groups. Without that criterion, and also when only
the participants who received all the intended immuni-
zations are considered, efficacy was weaker and non-
significant (26%, p = 0.08 and 0.16, respectively). Thus,
the outcome of the trial was rather fragile. The apparentvaccine efficacy declined from 60% for the first year to
31% for the 3.5-year post-vaccination period, although
with wide confidence intervals because of the small
number of infections [5,26,27]. Since Ab titers to gp120
vaccines decline rapidly [3,15], it might be conjectured
that the peak responses contribute to the higher efficacy
at the earlier times. There is, however, an alternative ex-
planation for the weakening efficacy of a vaccine [27].
Thus, if the exposure of the study participants to the
virus or their susceptibility to infection varies equally
within each group, high-risk subjects will be depleted
earlier among placebo recipients than vaccinees, pro-
vided the vaccine has any activity against high-risk trans-
mission events. The infection-rate ratio for vaccinees
over placebo recipients will then increase, i.e. the appar-
ent vaccine efficacy will decline over the follow-up
period. Unlike the waning of a protective adaptive im-
mune response, this predicted behavior of the cohort
also explains why there was a declining infection rate in
the RV144 placebo group [27]. The above epidemio-
logical phenomenon, therefore, weakens any evidence
for a causal link between changes in the immune re-
sponse and apparent protection. It cannot invalidate the
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and placebo groups, but it does encourage a search for
innate-immune or other susceptibility factors that
modulate infection rates in both groups. As indicated
above, the intriguing associations observed in the results
of three trials (Vax004, STEP, and RV144; the Vax003
results were not analyzed in a relevant manner) should
motivate this kind of investigation.
Augmenting the design of both trials and experiments
To improve the interpretation of vaccine-induced pro-
tection, Follmann has proposed two amplifications of
trial design [28]. The first stratagem involves giving all
participants an irrelevant vaccination at baseline and
quantifying the responses to that immunogen. Alterna-
tively, non-HIV-1 proteins expressed from a viral vector,
given to both the vaccine and placebo groups, could
serve as irrelevant immunogens in both humans and
animals. Correlating the responses to the HIV-1 and ir-
relevant immunogens among the vaccinees would then
allow a prediction of how the placebo subjects would
have responded to the HIV-1 immunogen had they
received it, i.e. the counterfactual scenario. At the end of
the trial, the additional information would differentiate
between two distinct hypotheses of how immune
responses to the HIV-1 vaccine relate to protection. First,
if the HIV-1-specific immune response were a CoP, the
infection rate among the placebo subjects should not
vary with the irrelevant response, and therefore not with
the projected response they would have had to the HIV-1
immunogen. Second, if instead the vaccinees’ responses
to the HIV-1 immunogen were merely an indirect mar-
ker for inherent resistance to infection (including innate
responses not elicited by the HIV-1 immunogens), then
the infection rates would be correlated with the irrele-
vant responses to similar extents in the two groups
(Figure 1).
The irrelevant-immunogen approach would only work
when the HIV-1-specific and irrelevant responses correl-
ate so strongly that the former can be counterfactually
projected from the latter in the placebo group (Figure 1).
A second stratagem was therefore devised in which, at
the end of the trial, all the uninfected placebo subjects
would receive exactly the same HIV-1-vaccine regimen
as the vaccinees got at the start [28]. Then, provided
each subject’s responsiveness to the vaccine is constant
over the time span of the trial, and if the HIV-1 immu-
nogen elicited a CoP, the responses of the uninfected
placebo recipients and the total vaccinee group should
be similar, i.e. lower than for uninfected vaccinees and
higher than for the subsequently infected vaccinees. And
if the responses to the HIV-1 immunogen were merely
markers of reduced susceptibility to infection, the unin-
fected subjects in the two groups should react similarly,i.e. both subsets should have stronger responses than the
subsequently infected vaccinees had at the correspond-
ing time after immunization.
The logistic complexities, and costs, of these augmen-
ted trial designs would surely be formidable. But their
application might have differentiated between a causal
and a susceptibility-marker hypothesis to explain the in-
verse association between infection risk and the magni-
tude of the anti-gp120 response in the Vax004 trial in
which the vaccine was not protective overall [3,21]. In
contrast, the surprising outcome of the STEP trial - that
the responses to the adenovirus vector were associated
with increased risk among vaccinees and decreased risk
among the placebo recipients - illustrates a potential pit-
fall of the irrelevant-immunization approach. Thus, os-
tensibly irrelevant immunogens such as an adenovirus
vector might actually affect susceptibility to infection
differently in the trial groups. Regarding the RV144 trial,
as for Vax004, questions remain about any causal role
for Ab responses that correlate inversely with the risk of
infection [17]. Specifically, however, if the weak Ab
responses to the RV144 Env immunogens contributed to
the slight net protection, they might have done so only
in a subset of volunteers with other, particularly benefi-
cial, adaptive or innate immune responses. Composite
effects of this nature might have been discernible had
the trial design been augmented.Searching for correlates of protection in case–control
analyses of human trials
When the natural immune-mediated eradication of viral
infection is followed by life-long immunity, as happens
with many common viruses [15], vaccine development
has a target to aim at: the immune correlates of protec-
tion. But this does not apply to HIV-1, for no instance of
its immune clearance has been proven despite the many
millions of infections. The closest analogues of natural
immunity available are therefore the immune responses
to chronic HIV-1 infection. Furthermore, the genetic di-
vergence among HIV-1 strains makes superinfection
readily detectable, which allows investigations of
whether the responses to chronic infection protect. The
results are daunting: superinfection rates are similar to
primary infection rates in comparable populations
[29,30]. Furthermore, at the time of infection, NAb
titers are not consistently lower in individuals who ac-
quire superinfection than those who do not [31]. Sup-
pose, however, the strongest NAb responses of infected
individuals really do reduce the risk of superinfection.
The overall lack of protection against superinfection
across a cohort might then be explained by the counter-
acting effect of a raised susceptibility to a second HIV-1
infection. Chronic inflammation and damaged innate
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how such an increase in susceptibility could arise.
Even against such a complex background, it is inform-
ative to compare the NAb responses of those who ac-
quire superinfection with the neutralization capacity
conferred by protective passive immunization, with the
corresponding NAb responses to vaccines in macaque
experiments, and with the humoral responses that cor-
relate inversely with the risk of infection in vaccine trials
and that have been implicated as protective.
Neutralizing titers of macaque plasma after passive
immunization with polyclonal NAbs confer different
degrees of protection against intravenous challenge with
75 TCID50 of SHIV-DH12. Thus, an EC50 in the TZM-bl
assay of 1/4500 corresponded to 90% in vivo protection,
while one of 1/230 gave 50% [32]. These neutralization
titers may be compared with those against viruses super-
infecting humans: in the same assay, the EC50 titers of
autologous sera from soon before the superinfection
event ranged from undetectable to 1/1000 and were
similar for matched controls who did not become super-
infected [31]. The lack of definite protection against
human superinfection might, therefore, have been pre-
dicted by extrapolation from the macaque passive
immunization experiments. The routes of infection in
the two scenarios are, of course, different - the human
subjects were heterosexually exposed women, whereas
the macaques were challenged intravenously. Further-
more, the plasma titer of infused NAbs did not correlate
with protection of macaques against vaginal challenge by
600 TCID50 of SHIV-89.6PD, but vaginal fluid NAb con-
centrations did correlate [20]. The NAb titers in the va-
ginal fluids of superinfected women are not known,
although in general such titers are markedly lower than
those in plasma [33]. Overall, we know too little about
human superinfection to infer what local levels of
vaccine-induced NAbs might minimally be required to
prevent mucosal infection.
In the RV144 trial, IgG reactive with the hyper-
variable gp120 V1V2 region was detected at slightly
higher levels in plasma from uninfected vaccinees than
from those who later became infected. This outcome oc-
curred only with a scaffolded V1V2 fragment as the
ELISA antigen, and not with V2 peptides or V1V2-
containing gp120s. The association between V1V2 Abs
and reduced risk was dampened by the presence of IgA
Abs that bound to a soluble uncleaved gp140 protein, or
to a gp120 C-terminal peptide. Nevertheless, this IgA re-
activity was not itself associated with an increased risk
of infection for vaccinees compared with placebo con-
trols [17]. Also, among the lowest Env-IgA responders,
both ADCC (Ab-dependent cellular cytotoxicity) and
NAbs effective against sensitive HIV-1 strains were
weakly associated with protection. It was thereforehypothesized that IgA molecules counteract IgG effector
functions [17]. Such a contention is, however, problem-
atic. Since the epitope specificities of the two isotypes
differ, the molecular basis for any such blocking effect is
unclear. Moreover, anti-Env IgA titers are considerably
lower than the corresponding IgG titers, raising ques-
tions of how IgA could effectively block IgG binding. It
should also be recalled that any Ab that can compete
with a NAb for binding to functional Env trimers is
likely itself to be neutralizing [34]. The hypothesis that
V1V2-reactive IgG conferred protection also raises im-
portant questions: How high are these V1V2-binding
capacities of IgG compared with those obtained in the
Vax004 trial? There, Env binding was much stronger,
but there was no protection against sexual transmission.
How strong and cross-reactive are the RV144 V1V2 Ab
responses compared with those elicited by infection,
during which there is no net protection against
superinfection?
It might be argued that because of how Env-reactive
IgA Abs statistically modulated the infection risk in the
RV144 trial, the CoP would be high V1V2-reactive IgG
combined with low Env-reactive IgA [35]. But then again
the question is whether Vax004 vaccinees and superin-
fected individuals did not have comparable or greater
V1V2-IgG over Env-IgA ratios prior to the relevant in-
fection events. If they did, why were they not protected?
How might anti-V1V2 antibodies protect? Or if they
do not directly protect, are they associated with a
mCoP? It should be recalled that if Ab binding to the
V1V2 region of functional Env reaches a sufficient occu-
pancy then HIV-1 infectivity is neutralized [34,36], and
yet the NAb responses in RV144 sera were so weak, nar-
row, and infrequent as to lack protective potential
[16,17]. One proposal is that V1V2 Abs block the bind-
ing of HIV-1 to the gut-homing integrin α4β7, the latter
interaction hypothetically promoting cell-to-cell spread
and the dissemination of newly transmitted founder
viruses [17,37]. This idea has been undermined by recent
observations that Abs to integrin α4β7 that block Env
binding do not prevent founder viruses from replicating
in vitro; only exceptional strains of little relevance to
transmission are inhibited [38].
Correlates of protection in the non-human primate model
Many experiments in non-human primate models have
yielded extensive information on the immunogenicity
and virological effects of various lentiviral vaccines [39-
42]. Here, we highlight a small subset of studies that
have provided robust evidence on correlates of risk.
These experiments have included sufficient numbers of
animals for definitive outcomes, and have used repeated
low-dose viral challenges, thereby adding further statis-
tical power. One such large-scale vaccine-efficacy study
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vaccination consisted of DNA priming with recombinant
adenovirus boosting, both vectors expressing the SIV-
mac239 gag-pol and env genes [9]. The 129 Indian-
origin rhesus monkeys were divided according to their
expression of MHC Class I alleles associated with effect-
ive T-cell responses. Only monkeys lacking such alleles
received the neutralization-resistant isolate, as a multiple
low-dose rectal challenge. The vaccine did not protect
significantly against acquisition but did suppress viral
loads. In contrast, monkeys challenged with the more
neutralization-sensitive SIVsmE660 strain were signifi-
cantly protected against acquisition regardless of MHC
genotype, but only those with favorable Class I alleles
showed signs of viral-load suppression after infection.
Thus, the vaccine did not protect from infection with
a challenge virus, SIVmac251, closely related to the vac-
cine strain, but did protect against a genetically more
distant one, SIVsmE660. Both the immunological sensi-
tivity and the replicative capacity of the two viruses
could influence whether protection from infection
occurs. A post-hoc analysis of another genetic host fac-
tor, TRIM5 polymorphism, revealed that infection-
restrictive genotypes were associated with protection
against infection in both the vaccine and control groups
[9]. Animals with the restrictive TRIM5 genotypes were
nearly all protected from acquisition by the vaccine, but
those with permissive TRIM5 genotypes also had signifi-
cantly lower infection rates than the corresponding con-
trols, which had a particularly high rate of infection.
The relative contributions to prevention of infection
by several adaptive and innate immune variables were
also evaluated by logistic regression. Among animals
with favorable MHC alleles, the restrictive TRIM5 gen-
otypes were strongly associated with protection from
infection, while for the other macaques NAbs and Env-
specific CD4+ T-cells were the best correlates [9]. The
dependency of vaccine efficacy on the genetic make-up
of the animals suggests that protection mechanisms are
multi-factorial.
A different vector-based SIV vaccine protected
against infection by the robust SIVmac251 strain in a
study where the frequencies of restrictive and permis-
sive TRIM5 genotypes were balanced among the groups
[6]. Gag-Pol proteins, with or without Env, were
expressed from different combinations of DNA, modi-
fied vaccinia Ankara (MVA) virus, and adenovirus vec-
tors Ad26 and Ad35. Protection against SIVmac251
acquisition correlated with total anti-Env Ab signals,
unlike protection against SIVsmE660 in the previous
study, but was again linked to NAb responses, which
were weak. A parallel with the human RV144 trial was
suggested in that V2-specific Abs were associated with
protection against infection, although the two studiesused different V2-containing antigens and assays [6,17].
Moreover, anti-Env trimer titers also correlated with
protection against infection [6]. It is unknown whether
similar correlations would be observed for Abs to other
SIV antigens (e.g., p24), as alternative measures of the
humoral immune response to the vaccine. The magni-
tude and breadth of Gag CTL responses correlated
with post-infection viremic control, but so did anti-Env
Ab, tier-1 NAb, ADCC, ADCVI, and Env-specific
CD4+ T-cell effector-memory responses. Of note is that
ADCC, a potential protective mechanism for non-
neutralizing Abs, was only weakly associated with pro-
tection against infection in the human RV144 trial but
strongly linked to viral control in the macaque study
[6,17]. Overall, important questions remain to be
answered about which vaccine responses are protective
mechanisms, which are only immune markers of suscep-
tibility, and about how variables in either category are
influenced by host genetics.
In a suggestive parallel to the Vax004 result, Env
expressed from a replicating adenovirus-5 vector did not
protect macaques against multiple low-dose SIVmac251
rectal challenges; but the infection rate in the Env-
vaccine group was significantly lower for animals with
high levels of Env-specific sIgA antibodies in rectal
secretions than for those with low levels [43]. Rectal
anti-Env sIgA antibodies were therefore suggested to be
a protective mechanism [43]. As there was no overall
protection in the experiment, however, the highest levels
of rectal Env-specific sIgA antibodies could only have
had any protective effect if the vaccine also exerted a
counteracting effect that enhanced the rate of infection
(Figure 1). The invocation of a counterbalance and a
zero-sum effect are necessary, just as in the case of anti-
gp120 responses in the non-protective Vax004 trial (see
above).
In a study where macaques were immunized with
DNA and a vaccinia vector expressing SIVmac239 Gag-
Pol and Env, a correlation was found between the num-
ber of rectal SIVsmE660 challenges required for infection
and an “avidity index” of Env-specific serum IgG [44].
The “avidity index” is commonly used [9,17,43]. It mea-
sures the capacity of Abs to bind Env in the presence of
chaotropic ions and thus partly reflects Ab affinity for
denatured Env proteins [45]. Ab reactivity with dena-
tured Env could presumably only be an indirect marker
of any mechanism that is active in vivo; if so, it would
not qualify as an mCoP but could possibly be an nCoP.
If, however, the imprecision of the “avidity index” and
the very small range (30-45%) of its average values for
animals infected after few or several challenges are taken
into account [44], the predictive value of this variable
vanishes. Furthermore, the subtle relationship between
“avidity index” and infection status was only observed
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immunizations: the macaques given only the vaccinia-
based vaccine were equally well protected, but there was
no correlation between risk and their “avidity index”
values, which were higher than in the combination group
[44]. It is of note that neither T-cell responses, rectal
IgA, ADCC, nor NAbs correlated with protection in this
study. In conclusion, the mCoP in this study remains
unknown.
Since the RV144 case–control study has generated the
hypothesis that V1V2-specific Abs are protective, it is
worth analyzing vaccine regimens that have proven
much more effective than RV144 while specifically ex-
cluding V2 epitopes from the immunogen. Complete
protection of macaques from rectal SHIV-SF162P4 chal-
lenge was achieved through immunization with V2-
deleted SF162 Env expressed from an alphavirus vector,
followed by boosting with a soluble form of the V2-
deleted Env trimer [46]. But the extent of the Ab
responses associated with protection against infection
overlapped considerably between protected and infected
animals. Hence, for the most part, the Ab reactivities
were not sufficient for protection. In a different study,
an attenuated, V1V2-deleted variant of SIVmac239 con-
ferred strong control of viremia when the macaques
were challenged with the wild type virus [47]. Important
anti-viral mechanisms clearly operate independently of
V2 and probably target epitopes that are more conserved
and hence more exploitable through vaccination.
Cooperative immune functions
Active immunization engages multiple aspects of the im-
mune system with innumerable inter-related effects.
Synergistic mechanisms are difficult to identify in
immune-correlates analyses; each component contribut-
ing to the synergy may be necessary but insufficient for
the observed protection. And vaccine-induced responses
might also synergize with, or be antagonized by, host
variables that are unaffected by the vaccine.
After passive immunization, the prevention of SHIV
infection by a broadly active NAb was enhanced by, but
did not depend on, the Fc-receptor binding capacity of
the IgG [48]. Protection might therefore sometimes de-
pend on collaborations between NAbs and some cellular
or other aspect of the immune system. Any damage to
these other immune factors could help explain why pre-
existing high levels of NAbs do not appear to protect
already infected people against HIV-1 superinfection
(see above).
Are vaccine effects on acquisition and viral loads com-
pletely independent? In animal experiments, ADCC has
been associated with lower viral loads, just as have CTL
responses [6]. Such similarities might be expected since
both responses kill infected cells. Yet, in the RV144 trialthere was a weak tendency for ADCC to be associated
with protection against acquisition, whereas in the
Vax004 trial ADCVI activity, like Env-binding Abs, was
inversely associated with the risk of acquisition despite
the lack of overall protection [21]. Both NAb and CTL
responses were associated with lower viral loads after
multiple rectal SHIV challenges of monkeys immunized
with a combination of Env trimers and Gag-Pol particles
[49]. In other studies, CTL responses did not enhance
protection against infection by systemically infused
NAbs [50], but combining an entry-inhibitor microbicide
(which is comparable to mucosal NAbs) with a vaccine
gave both lower viral loads and lower acquisition than
either intervention alone [51]. When statistical associa-
tions are analyzed, each component in a multi-factorial,
synergistic mCoP combination is likely to be imperfectly
correlated with protection, because variation among the
other factors will blur the relationships. The difficulty of
identifying such combined causes may explain why
mCoPs in human and monkey studies are so elusive.
Conclusion
The search for inducible immune responses that protect
against HIV-1 infection is delicate and error-prone, par-
ticularly when protection is weak or marginal [5,17]. If a
vaccine only needed to elicit IgG recognizing with V1V2
epitopes with test-strain sequences, presented on mono-
meric scaffolds, the task of vaccination would be facile
(and would surely have been accomplished already by
gp120 vaccines). But it will be much harder if Abs cross-
reacting with unknown V1V2 sequences - presented in
their native trimeric form on the potentially transmitted
virions - are required. Such antibodies would, ipso facto,
be cross-neutralizing, which remains a prime goal of
many vaccine strategies [52,53]. The assertion “RV144
vaccine data [. . .] showed the protective ability of the V2
antibodies” [37] is completely unsubstantiated by the
available data. The future may reveal that the hypothesis
of protection by V1V2 antibodies is more of a cop-out
than an outed CoP [54]. How and to what extent IgA of
any specificity could counteract protective IgG responses
is also utterly unclear. Overall, the RV144-inspired hy-
potheses of protection are hard to fit into an explanatory
mechanistic framework. The possibility remains that in-
direct associations are being pursued, thereby distracting
attention from the search for directly protective
responses [54].
While acknowledging the logistic complications, we
support Follmann’s arguments for augmenting the de-
sign of vaccine studies by administering irrelevant
immunogens to both vaccinees and placebo subjects,
and by performing post-trial vaccination among unin-
fected placebo recipients. These stratagems could be
adopted in both human trials and animal experiments,
Klasse and Moore Retrovirology 2012, 9:80 Page 8 of 10
http://www.retrovirology.com/content/9/1/80for they would facilitate a sifting of causal correlates of
protection from adventitiously associated factors. Some
adaptive immune responses might only be effective
when they act in unison with innate responses and con-
stitutive resistance factors. Furthermore, if host factors
that determine the strength of vaccine responses vary
widely in a population, so will vaccine efficacy. The
causes of such variation and of factors modulating sus-
ceptibility might be explored through systems-biological
approaches, which have elucidated host determinants of
effective vaccination against the influenza and yellow-
fever viruses [55,56]. Genome-wide association studies
of cohorts lacking protective CCR5 variants have not yet
identified host genotypes influencing HIV-1 acquisition,
but complementary methods, such as large-scale sequen-
cing, may prove fruitful [57,58]. Exploring the genetic
basis for variable responses to HIV-1 immunogens may
also be valuable. The host’s microbiome and previous
exposures to immunogens might mold vaccine responses
[59], in which case combinations of host-genome and
microbiome traits could influence vaccine efficacy. In
summary, a comprehensive causal analysis of protection
will require a dissection of complex interactions among
innate and adaptive immune responses as well as other
host predispositions and environmental factors.
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